ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors | GenomeWeb

Originally published June 5.

CHICAGO – Roche's personalized melanoma drug Zelboraf (vemurafenib) – the first BRAF inhibitor to enter the market and one of the few drugs to significantly improve survival in patients with advanced disease – is likely to face significant competition in coming years from next-generation agents that will attempt to mirror or improve upon the agent's efficacy and safety against skin cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.